This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Préville, X. Articles by Leclerc, C. Search for Related Content PubMed PubMed Citation Articles by Préville, X. Articles by Leclerc, C.

Eradication of Established Tumors by Vaccination With Recombinant Bordetella pertussis Adenylate Cyclase Carrying the Human Papillomavirus 16 E7 Oncoprotein

¹ BT PHARMA, Biotop, ² Unité Postulante de Biochimie des Interactions Macromoléculaires, Centre National de la Recherche Scientifique, and ³ Unité de Biologie des Régulations Immunitaires, Institut National de la Sante et de la Recherche Medicale E352, Institut Pasteur, Paris Cedex 15, France

Requests for reprints: Xavier Préville, Unité de Biologie des Régulations Immunitaires, Institut National de la Sante et de la Recherche Medicale E352, Institut Pasteur, 25-28 rue de Dr Roux, 75724 Paris Cedex 15, France. Phone: 33-1-4061-3910; Fax: 33-1-4568-8540; E-mail: xprevil{at}pasteur.fr.

High-risk human papillomaviruses (HPV) such as HPV16 are associated with the development of cervical cancer. The HPV16-E6 and HPV16-E7 oncoproteins are expressed throughout the replicative cycle of the virus and are necessary for the onset and maintenance of malignant transformation. Both these tumor-specific antigens are considered as potential targets for specific CTL-mediated immunotherapy. The adenylate cyclase (CyaA) of Bordetella pertussis is able to target dendritic cells through specific interaction with the _Mß₂ integrin. It has been previously shown that this bacterial protein could be used to deliver CD4⁺ and CD8⁺ T cell epitopes to the MHC class II and class I presentation pathways to trigger specific Th and CTL responses in vivo, providing protection against subsequent viral or tumoral challenge. Here, we constructed recombinant CyaA containing either the full sequence or various subfragments from the HPV16-E7 protein. We show that, when injected to C57BL/6 mice in absence of any adjuvant, these HPV16-recombinant CyaAs are able to induce specific Th1 and CTL responses. Furthermore, when injected into mice grafted with HPV16-E7-expressing tumor cells (TC-1), one of these recombinant proteins was able to trigger complete tumor regression in 100% of the animals tested. This therapeutic efficacy compared favorably to that of strongly adjuvanted peptide and was marginally affected by prior immunity to CyaA protein. This study represents the first in vivo demonstration of the antitumoral therapeutic activity of recombinant CyaA proteins carrying human tumor–associated antigens and paves the way for the testing of this vector in clinical trials.

Key Words: cancer • immunotherapy • vaccination • HPV16

This article has been cited by other articles:

				S. R. Paccani, F. D. Molin, M. Benagiano, D. Ladant, M. M. D'Elios, C. Montecucco, and C. T. Baldari Suppression of T-Lymphocyte Activation and Chemotaxis by the Adenylate Cyclase Toxin of Bordetella pertussis Infect. Immun., July 1, 2008; 76(7): 2822 - 2832. [Abstract] [Full Text] [PDF]

				P. Berraondo, C. Nouze, X. Preville, D. Ladant, and C. Leclerc Eradication of Large Tumors in Mice by a Tritherapy Targeting the Innate, Adaptive, and Regulatory Components of the Immune System Cancer Res., September 15, 2007; 67(18): 8847 - 8855. [Abstract] [Full Text] [PDF]

				S. H. Bae, Y.-J. Park, J.-B. Park, Y. S. Choi, M. S. Kim, and J.-I. Sin Therapeutic Synergy of Human Papillomavirus E7 Subunit Vaccines plus Cisplatin in an Animal Tumor Model: Causal Involvement of Increased Sensitivity of Cisplatin-Treated Tumors to CTL-Mediated Killing in Therapeutic Synergy Clin. Cancer Res., January 1, 2007; 13(1): 341 - 349. [Abstract] [Full Text] [PDF]

				S. Hervas-Stubbs, L. Majlessi, M. Simsova, J. Morova, M.-J. Rojas, C. Nouze, P. Brodin, P. Sebo, and C. Leclerc High Frequency of CD4+ T Cells Specific for the TB10.4 Protein Correlates with Protection against Mycobacterium tuberculosis Infection. Infect. Immun., June 1, 2006; 74(6): 3396 - 3407. [Abstract] [Full Text] [PDF]

				L. Majlessi, M. Simsova, Z. Jarvis, P. Brodin, M.-J. Rojas, C. Bauche, C. Nouze, D. Ladant, S. T. Cole, P. Sebo, et al. An Increase in Antimycobacterial Th1-Cell Responses by Prime-Boost Protocols of Immunization Does Not Enhance Protection against Tuberculosis Infect. Immun., April 1, 2006; 74(4): 2128 - 2137. [Abstract] [Full Text] [PDF]

				K. A. Aires, A. M. Cianciarullo, S. M. Carneiro, L. L. Villa, E. Boccardo, G. Perez-Martinez, I. Perez-Arellano, M. L. S. Oliveira, and P. L. Ho Production of Human Papillomavirus Type 16 L1 Virus-Like Particles by Recombinant Lactobacillus casei Cells Appl. Envir. Microbiol., January 1, 2006; 72(1): 745 - 752. [Abstract] [Full Text] [PDF]

				L. G. Bermudez-Humaran, N. G. Cortes-Perez, F. Lefevre, V. Guimaraes, S. Rabot, J. M. Alcocer-Gonzalez, J.-J. Gratadoux, C. Rodriguez-Padilla, R. S. Tamez-Guerra, G. Corthier, et al. A Novel Mucosal Vaccine Based on Live Lactococci Expressing E7 Antigen and IL-12 Induces Systemic and Mucosal Immune Responses and Protects Mice against Human Papillomavirus Type 16-Induced Tumors J. Immunol., December 1, 2005; 175(11): 7297 - 7302. [Abstract] [Full Text] [PDF]